Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0461929603
Mon, 25.04.2022
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today announced that its project company Baliopharm has achieved an important R&D milestone in the development of the product candidate ATROSIMAB for the treatment of Non-alcoholic steatohepatitis (NASH) and potentially other chronic liver diseases. The phase 1 of the in-vivo trial evaluating the safety, tolerabili [ … ]
Thu, 21.04.2022
Xlife Sciences AG
Xlife Sciences AG (SIX: XLS) today announced that due to the change from the Munich Stock Exchange (unregulated market ['Freiverkehr'] to the regulated market of the SIX Swiss Exchange (SME Segment 'Sparks') and the related change of auditors, the company will publish its annual report 2021 newly on 29 April 2022.
Financial calendar
Annual Report [ … ]
Fri, 11.02.2022
Xlife Sciences AG
Media Release
Zurich, February 11, 2022, 7 am CET
Xlife Sciences' shares begin trading on SIX Swiss Exchange
- As of 3 pm CET today, the shares of Xlife Sciences AG will be traded on SIX Swiss Exchange - as the first company in the new "Sparks" segment.
- The reference price is CHF 44.71 and corresponds to the closing price of EUR 42.20 at the [ … ]
Tue, 08.02.2022
Xlife Sciences AG
Media Release
Zurich, February 8, 2022, 8 pm CET
Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange
Xlife Sciences AG (XLS DE) today has published the prospectus for its intended listing on the "Sparks" segment of SIX Swiss Exchange. The listing and commencement of trading is scheduled for February 11, 2022 (from 3 pm CET*), as [ … ]
Tue, 01.02.2022
Xlife Sciences AG
Media Release
Zurich, February 1, 2022, 8 pm CET
Xlife Sciences: Listing and first trading day on the "Sparks" segment of SIX Swiss Exchange expected for February 11, 2022
Xlife Sciences AG (XLS DE) intends to list and commence trading of its shares on the SME equity segment "Sparks" of SIX Swiss Exchange on February 11, 2022, under the stock exch [ … ]
Wed, 26.01.2022
Xlife Sciences AG
Media Release
Zurich, January 26, 2022, 7 am CET
Xlife Sciences raises CHF 5.0 million through capital increase
Xlife Sciences AG (XLS DE) has decided and executed a capital increase on January 25, 2022. It consists of the issuance of 108'495 new shares at a price of CHF 46.20 each in a private placement. In addition, 31'360 new shares were issued [ … ]
Mon, 10.01.2022
Xlife Sciences AG
Media Release
Xlife Sciences plans listing on the "Sparks" segment of SIX Swiss Exchange
- Listing on the new "Sparks" segment of SIX Swiss Exchange for small and medium-sized companies is planned for Q1 2022, subject to market environment
- Xlife Sciences AG is a Swiss company focused on the value development and commercialization of promising [ … ]
Thu, 18.11.2021
Xlife Sciences AG
DGAP Ad-hoc-Service
November 18, 8 pm CET
Media release
Xlife Sciences (XLS DE) explores listing on SIX Swiss Exchange
Xlife Sciences, a Swiss company developing new technologies and treatments in the life sciences sector and currently admitted to trading on the Munich Stock Exchange, today announced that it is exploring the possibility of a li [ … ]
Tue, 26.10.2021
Xlife Sciences AG
MEDIA INFORMATIONXlife Sciences AG (XLS DE): Partnership with Vision 2030
Xlife Sciences AG is elected as Innovation Partner for Saudi Arabia Xlife Sciences AG has signed a strategic partnership with the development organization Peace City World as part of the Vision 2030 future program. Peace City World is the official developer of four Smart Cit [ … ]
Thu, 10.06.2021
Xlife Sciences AG
PRESS RELEASEXlife Sciences AG (XLS DE): Breakthrough in Drug Development
First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active sub [ … ]